1. Home
  2. ROIV vs CRS Comparison

ROIV vs CRS Comparison

Compare ROIV & CRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$28.68

Market Cap

20.7B

Sector

Health Care

ML Signal

HOLD

Logo Carpenter Technology Corporation

CRS

Carpenter Technology Corporation

HOLD

Current Price

$434.75

Market Cap

21.3B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROIV
CRS
Founded
2014
1910
Country
United Kingdom
United States
Employees
N/A
4500
Industry
Biotechnology: Pharmaceutical Preparations
Steel/Iron Ore
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
20.7B
21.3B
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
ROIV
CRS
Price
$28.68
$434.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
7
Target Price
$27.56
$394.14
AVG Volume (30 Days)
4.1M
714.2K
Earning Date
05-28-2026
04-29-2026
Dividend Yield
N/A
0.19%
EPS Growth
N/A
100.54
EPS
N/A
4.52
Revenue
$29,053,000.00
$2,157,700,000.00
Revenue This Year
N/A
$9.17
Revenue Next Year
$878.32
$10.54
P/E Ratio
N/A
$94.73
Revenue Growth
N/A
20.03
52 Week Low
$9.57
$163.06
52 Week High
$30.33
$428.50

Technical Indicators

Market Signals
Indicator
ROIV
CRS
Relative Strength Index (RSI) 57.95 64.06
Support Level $26.45 $297.11
Resistance Level $30.33 N/A
Average True Range (ATR) 0.96 19.09
MACD 0.02 3.92
Stochastic Oscillator 95.23 89.49

Price Performance

Historical Comparison
ROIV
CRS

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

About CRS Carpenter Technology Corporation

Carpenter Technology Corp supplies specialty metals to a variety of end markets, including aerospace and defense, industrial machinery and consumer durables, medical, and energy, among others. The company's reportable segments include; Specialty Alloys Operations and Performance Engineered Products. It generates maximum revenue from the Specialty Alloys Operations segment. The SAO segment is comprised of the company's alloy and stainless steel manufacturing operations. This includes operations performed at mills predominantly in Reading and Latrobe, Pennsylvania, and surrounding areas as well as South Carolina and Alabama. Geographically, the company derives its maximum revenue from the United States and the rest from Europe, Asia Pacific, Mexico, Canada, and other regions.

Share on Social Networks: